Today: 30 June 2026
Browse Category

NYSE:SNOW 14 January 2026 - 27 February 2026

Experian share price rises as ChatGPT insurance app launch puts AI strategy back in focus

Experian share price rises as ChatGPT insurance app launch puts AI strategy back in focus

London, Feb 13, 2026, 08:55 GMT — Regular session Experian PLC climbed 1.6% to 2,447 pence as of 0855 GMT Friday, tacking on 39 pence from Thursday’s close. The credit data firm is rolling out new AI-related offerings and continuing its buyback. Shares moved in a range between 2,402 and 2,459 pence, still hovering just above the 52-week low of 2,353 pence.
13 February 2026
·····
Cloud computing stocks bounce back — SKYY jumps, but Amazon’s AI spending plan keeps nerves high

Cloud computing stocks bounce back — SKYY jumps, but Amazon’s AI spending plan keeps nerves high

New York, Feb 8, 2026, 13:36 EST — The market has closed. Cloud computing names wrapped up Friday in the green, with key cloud ETFs notching gains—First Trust Cloud Computing ETF up 4.4%, WisdomTree Cloud Computing Fund ahead 3.5%, and Global X Cloud Computing ETF climbing 2.2%. Amazon, though, dropped 5.6% as investors balked at the mounting price tag of its AI buildout. Snowflake soared 7.5%, while Microsoft edged up 1.8%.
8 February 2026
·······
Nasdaq slides as AMD forecast and AI disruption fears hammer tech again

Nasdaq slides as AMD forecast and AI disruption fears hammer tech again

The S&P 500 and Nasdaq dropped Wednesday, pressured by renewed selling in software and chip shares. Advanced Micro Devices slumped following its earnings outlook. The Dow, however, nudged up as investors favored sectors viewed as more affordable or stable. The selloff hits now as the market grapples with two conflicting forces: massive AI investments and the risk that AI tools could disrupt the software companies that powered the previous cycle. This tug-of-war unfolds amid a packed earnings week.
4 February 2026
········
Cloud computing stocks: SKYY ETF slides as Alphabet, Amazon earnings and jobs data loom

Cloud computing stocks: SKYY ETF slides as Alphabet, Amazon earnings and jobs data loom

New York, Jan 31, 2026, 13:41 ET — Market closed. Cloud computing stocks head into next week’s U.S. session facing earnings from two major cloud providers along with a crucial jobs report, following a turbulent finish to January that weighed on costly growth names.
31 January 2026
··········
Cloud computing stocks face a packed week as Amazon job cuts loom and Fed meets

Cloud computing stocks face a packed week as Amazon job cuts loom and Fed meets

NEW YORK, Jan 24, 2026, 12:49 — Market closed. Amazon is back in the spotlight as cloud computing stocks head into next week, following a Reuters report that the company plans another wave of corporate job cuts starting as early as Tuesday. The layoffs will impact Amazon Web Services and are part of a broader effort to reduce roughly 30,000 white-collar roles, after 14,000 were cut in October. CEO Andy Jassy emphasized that the moves are “not really financially driven” but about “culture.”
24 January 2026
········
Amazon’s Europe-only AWS cloud launch puts cloud computing stocks in focus before Tuesday’s open

Amazon’s Europe-only AWS cloud launch puts cloud computing stocks in focus before Tuesday’s open

NEW YORK, Jan 17, 2026, 13:45 EST — Market closed Cloud computing stocks enter the extended U.S. weekend under fresh scrutiny after Amazon’s AWS rolled out a cloud service based solely in Europe. The move targets clients worried about data access and legal jurisdiction.
17 January 2026
········
1 2 3 4 5

Stock Market Today

  • Talawar Therapeutics to List Nasdaq as It Raises $285M for Atopic Dermatitis Drug
    June 30, 2026, 8:18 AM EDT. Talawar Therapeutics will go public on Nasdaq as 'TLWR' after pulling in $225 million through a PIPE plus $60 million from SPAC JATT II Acquisition, raising $285 million in total. The New Jersey biotech is developing TALA-125, an IL-13/IL-18 bispecific antibody aimed at atopic dermatitis, and is going up against Sanofi and Regeneron's top-selling Dupixent. Talawar says this new approach could get past limits of current therapies by targeting two immune pathways. The company expects to start Phase IIb trials by early 2027, with data coming in late 2028. AD sales could hit $22.4 billion by 2033, even as the field still sees unmet need.
Go toTop